Q-omics provides the consensus-scored MIR181A1HG profile across patient tissues and cancer cell-line models. MIR181A1HG expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR181A1HG is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, MIR181A1HG RNA expression shows 14,969 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, BLCA, and LSCC as cancer lineages where MIR181A1HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR181A1HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR181A1HG survival associations across molecular data types. MIR181A1HG RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR181A1HG RNA expression–survival associations across cancer types. High MIR181A1HG expression shows unfavorable associations in MESO, KIRC, ACC, OV and CESC, but favorable associations in LAML. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR181A1HG RNA expression.
This table summarizes MIR181A1HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR181A1HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR181A1HG shows lower tumor expression in KICH and higher tumor expression in BLCA, BRCA, STAD, HNSC and COAD. The BLCA box plot shows higher MIR181A1HG RNA expression in tumor versus normal tissue (log2 FC = +0.105, t-test p = .007).
This table shows molecular features associated with MIR181A1HG in patient tissues and cancer cell lines. In patient samples, MIR181A1HG shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
